Featured Research

from universities, journals, and other organizations

Elite controllers block integration of HIV DNA into host genome

Date:
September 19, 2011
Source:
American Society for Microbiology
Summary:
Alone among those infected with HIV-1, so-called elite controllers spontaneously maintain undetectable levels of viral replication even absent the benefit of anti-retroviral therapy. Now researchers show that in elite controllers, integration of HIV-1 DNA into the host chromosomes of CD4 T cells -- the main target cells of HIV-1 -- is markedly reduced in comparison to those whose infection has run a more normal course.

Alone among those infected with HIV-1, so-called elite controllers spontaneously maintain undetectable levels of viral replication even absent the benefit of anti-retroviral therapy. Now Mathias Lichterfeld of the Massachusetts General Hospital, Boston, and Xu Yu of the Ragon Institute show that in elite controllers, integration of HIV-1 DNA into the host chromosomes of CD4 T cells -- the main target cells of HIV-1 -- is markedly reduced in comparison to those whose infection has run a more normal course. "[Elite controllers] behave like people who get effective antiretroviral treatment, despite the fact that they don't," says Lichterfeld.

Related Articles


In the study, the researchers removed CD4 T cells from elite controllers, from random HIV-1 negative persons, and from HIV-1 infected persons with progressive disease, and infected those cells with HIV-1 in the laboratory. While HIV-1 successfully integrated into both reference populations' CD4 T cells far more effectively than into those of elite controllers, the researchers found higher levels of unintegrated, extrachromosomal HIV-1 DNA floating around in the elite controllers' CD4 T cells.

"Overall, this suggests that the process of chromosomal integration of HIV-1 is somehow inhibited in elite controllers," says Lichterfeld. Now poorly understood, the mechanism likely involves a synergistic interplay between multiple innate and adaptive immune defenses, he says.

"We think that these subjects can really teach us a lot about how immune-mediated control can work under real-life circumstances," says Lichterfeld. "If we were to understand in detail what's going on in these patients, we might be able to develop some sort of intervention that could protect people against HIV-1."

This report is consistent with a paper published earlier this year which showed that elite controllers have low levels of chromosomally integrated HIV-1 DNA, and higher levels of extrachromosomal, 2-LTR circular HIV DNA, as compared to patients on highly active anti-retroviral therapy (HAART) (PLoS Pathog. 7:e1001300).

The research is published in the September 2011 issue of the Journal of Virology.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. J. Buzon, K. Seiss, R. Weiss, A. L. Brass, E. S. Rosenberg, F. Pereyra, X. G. Yu, M. Lichterfeld. Inhibition of HIV-1 Integration in Ex Vivo-Infected CD4 T Cells from Elite Controllers. Journal of Virology, 2011; 85 (18): 9646 DOI: 10.1128/JVI.05327-11

Cite This Page:

American Society for Microbiology. "Elite controllers block integration of HIV DNA into host genome." ScienceDaily. ScienceDaily, 19 September 2011. <www.sciencedaily.com/releases/2011/09/110919113448.htm>.
American Society for Microbiology. (2011, September 19). Elite controllers block integration of HIV DNA into host genome. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/09/110919113448.htm
American Society for Microbiology. "Elite controllers block integration of HIV DNA into host genome." ScienceDaily. www.sciencedaily.com/releases/2011/09/110919113448.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins